Publications

Publications

Filter Results: (1,253) Arrow Down
Filter Results: (1,253) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 21 of 1,253 Results →

    Michael Beer

    MICHAEL BEER

    Mike Beer is the Cahners-Rabb Professor of Business Administration, Emeritus at the Harvard Business School and author Fit to Compete: Why Honest Conversations About Your Company’s... View Details

    • June 2024 (Revised December 2024)
    • Case

    Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital

    By: Joshua D. Margolis and Ahmed Dahawy
    Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
    Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
    Related
    • Research Summary

    Regulatory negotiations and risk communication

    In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details
    • Research Summary

    Entrepreneurial Finance and International R&D Management

    Walter Kuemmerle's research and teaching interests fall within the domain of knowledge and capital management in a global economy. His research focuses on international entrepreneurship and venture capital. He studies venture capital systems and entrepreneurship in... View Details
    • May 2021
    • Case

    The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease

    By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
    This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory... View Details
    Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Health Industry; United States
    Related
    • 2012
    • Article

    A Field Study on the Acceptance and Use of a New Accounting System

    By: V.G. Narayanan, Ranjani Krishnan and Jamshed J. Mistry
    This study examines the attitudes, use, and acceptance of a new accounting system in a pharmaceutical corporation that switched from an Activity Based Costing System to the Theory of Constraints System (TOC). Using structuration theory as a framework, we posit that... View Details
    Keywords: Theory Of Constraints; Structuration; Field Study; Accounting; Innovation and Invention
    Related
    • January 2018 (Revised January 2019)
    • Case

    ZappRx

    By: Jeffrey J. Bussgang and Olivia Hull
    In October 2015, ZappRx founder Zoe Barry is deciding between two business models for her health technology start-up. Her product, a software application that aims to expedite the prescription fulfillment process for patients with rare diseases, has attracted interest... View Details
    Keywords: Speciality Drugs; Hub Services; Pivot; Speciality Prescriptions; Health Care and Treatment; Customization and Personalization; Internet and the Web; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; Massachusetts
    Related
    • 15 Jan 2008
    • First Look

    First Look: January 15, 2008

      Working PapersCompetition in Modular Clusters Authors:Carliss Y. Baldwin and C. Jason Woodard Abstract The last twenty years have witnessed the rise of disaggregated "clusters," "networks," or "ecosystems" of firms. In these clusters the... View Details
    Keywords: Martha Lagace
    • August 2023
    • Case

    Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company

    By: Satish Tadikonda and Brad Prosek
    Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
    Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
    Related
    • 14 Aug 2007
    • First Look

    First Look: August 14, 2007

      Working PapersHedge Fund Investor Activism and Takeovers Authors:Robin Greenwood and Michael Schor Abstract We examine long-horizon stock returns around hedge fund activism in a comprehensive sample of 13D filings by portfolio investors between 1993 and 2006.... View Details
    Keywords: Martha Lagace

      Incentives for Bad Science

      Randomized controlled trials (RCTs) inform medical practice, health care delivery, follow-on research, regulation, and health policy. Yet, many RCTs are inadequately randomized, blinded, and reported. To analyze scientists' and firms' incentives to meet clinical trial... View Details
      • Web

      Strategy - Doctoral

      relationship between non-market experience and the use and outcome of patent strategies by pharmaceutical firms; the antecedents and consequences of corporate strategy decision-making, specifically focusing on divestitures and governance;... View Details
      • Research Summary

      Multinational Enterprises and Corporate Responsibility

      By: Nien-he Hsieh

      Multinational enterprises, especially those operating in developing economies, face wide-ranging demands to help persons whose basic needs are unmet. Pharmaceutical companies, for example, are asked to provide access to life-saving therapies to patients in countries... View Details

      • October 2012
      • Case

      GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)

      By: Toby Stuart and James Weber
      An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
      Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
      Related
      • December 2002
      • Article

      Knowledge Seeking and Location Choice of Foreign Direct Investment in the United States

      By: Juan Alcacer and Wilbur Chung
      To what extent do firms go abroad to access technology available in other locations? This paper examines whether and when state technical capabilities attract foreign investment in manufacturing from 1987-1993. We find that on average state R&D intensity does not... View Details
      Keywords: Knowledge Acquisition; Foreign Direct Investment; Research and Development; Information Technology; Production; Geographic Location; United States
      Related
      • 17 Apr 2014
      • HBS Seminar

      Paul Healy, Harvard Business School

      • November 2017
      • Case

      The 'Wonder Drug' That Killed Babies

      By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
      In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
      Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Pharmaceutical Industry; United States; United Kingdom; Australia; Germany; Europe
      Related
      • 15 May 2007
      • First Look

      First Look: May 15, 2007

        Working PapersI'll Have the Ice Cream Soon and the Vegetables Later: Decreasing Impatience over Time in Online Grocery Orders Authors:Todd Rogers, Katherine L. Milkman, and Max H. Bazerman Abstract How do decisions for the near future differ from decisions for the... View Details
      Keywords: Martha Lagace
      • 2011
      • Working Paper

      Managing Political Risk in Global Business: Beiersdorf 1914-1990

      By: Geoffrey Jones and Christina Lubinski
      This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks... View Details
      Keywords: History; Risk Management; Business History; Multinational Firms and Management; Corporate Strategy; Intellectual Property; Cooperation; Business and Government Relations; Germany
      Related
      • 05 Sep 2023
      • Book

      Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

      acid deficiency. When the drug was reformulated with folic acid, it passed its efficacy trials, eventually becoming a multibillion-dollar pharmaceutical that helped thousands of lung cancer patients. How to fail intelligently Edmondson,... View Details
      Keywords: by Michael Blanding